Healthcare News
Once-weekly eloralintide leads to 20% weight loss in Phase II trial
A multicenter team including Endeavor Health and Eli Lilly found that once-weekly eloralintide produced dose-dependent weight loss up to 20% over 48 weeks in adults with obesity or overweight without type 2 diabetes.
Popular weight-loss drugs show added heart protection for diabetes patients
Injectable weight-loss drugs can reduce the risk of serious cardiovascular events for people with type 2 diabetes. Researchers at the Technical University of Munich (TUM) and Harvard Medical School have demonstrated this result using insurance claims data.
Weight-loss surgery bests medical weight management for obesity-related risk mitigation
Bariatric surgery is associated with a significantly lower risk for developing major metabolic comorbidities compared with a medical weight management program for adults with obesity, according to a study published online Sept. 9 in JAMA Network Open.
Human-AI coaching models boost weight loss
Adding human coaches to artificial intelligence-powered weight-loss programs significantly boosts user success, underscoring the value of hybrid human-AI models in digital health, a new study suggests.
Study finds orforglipron taken orally once daily leads to significant body weight loss
New research presented at the Annual Meeting of the European Association for the Study of Diabetes in Vienna, Austria (Sept 15–19) and simultaneously published in NEJM shows that daily treatment with the new once-daily GLP-1 agonist orforglipron results in substantial weight loss in people living with obesity that do not have type 2 diabetes.